Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter double‑blind randomized trial of intravitreal conbercept versus aflibercept in wAMD
CTR20191391Phase 3Terminated
- Sponsor
- Chengdu Kanghong Pharmaceutical Group
- Start
- Sep 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of conbercept in exudative macular degeneration, sponsored by Chengdu Kanghong Pharmaceutical Group. Started Sep 2019; status: terminated.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20191391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191391.